Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals (XFOR)
:XFOR
RESEARCH TOOLSreports
Holding XFOR?
Track your performance easily
XFOR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $1.60
Previous CloseN/A
Volume769.31K
Average Volume (3M)3.59M
Market Cap
$78.66M
Enterprise Value$77.67M
Total Cash (Recent Filing)$3.04M
Total Debt (Recent Filing)$10.13M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Mar 13, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding170,546,460
10 Day Avg. Volume3,116,955
30 Day Avg. Volume3,587,222
Standard Deviation0.27
R-Squared0.00076
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)70.23
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue66.78
Enterprise Value/Gross Profit398.28
Enterprise Value/Ebitda12.91
Forecast
1Y Price Target
$1.75Price Target Upside280.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
X4 Pharmaceuticals News
PremiumCompany Announcements
X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion
Ownership Overview
11.64% Insiders
7.57% Mutual Funds
34.08% Other Institutional Investors
38.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XFOR FAQ
What was X4 Pharmaceuticals’s price range in the past 12 months?
X4 Pharmaceuticals lowest stock price was $0.26 and its highest was $1.60 in the past 12 months.
What is X4 Pharmaceuticals’s market cap?
X4 Pharmaceuticals’s market cap is $78.66M.
When is X4 Pharmaceuticals’s upcoming earnings report date?
X4 Pharmaceuticals’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were X4 Pharmaceuticals’s earnings last quarter?
X4 Pharmaceuticals released its earnings results on Nov 13, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.171 by -$0.009.
Is X4 Pharmaceuticals overvalued?
According to Wall Street analysts X4 Pharmaceuticals’s price is currently Undervalued.
Does X4 Pharmaceuticals pay dividends?
X4 Pharmaceuticals does not currently pay dividends.
What is X4 Pharmaceuticals’s EPS estimate?
X4 Pharmaceuticals’s EPS estimate is -0.17.
How many shares outstanding does X4 Pharmaceuticals have?
X4 Pharmaceuticals has 170,546,460 shares outstanding.
What happened to X4 Pharmaceuticals’s price movement after its last earnings report?
X4 Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.171. Following the earnings report the stock price went down -52.542%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals?
Among the largest hedge funds holding X4 Pharmaceuticals’s share is Perceptive Advisors LLC. It holds X4 Pharmaceuticals’s shares valued at 2M.
---
X4 Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.75 (280.43% Upside)
$1.75 (280.43% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.83%
12-Months-Change
Fundamentals
Return on Equity
-26.35%
Trailing 12-Months
Asset Growth
2.81%
Trailing 12-Months
Company Description
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
---
XFOR Company Deck
---
XFOR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted positive clinical trial results and strategic advancements for X4 Pharmaceuticals, particularly with mavorixafor's potential in chronic neutropenia and the successful launch of XOLREMDI. However, some concerns were noted regarding flat sales and early study discontinuations.Read More>---
XFOR Stock 12 Month Forecast
Average Price Target
$1.75
▲(280.43% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Zymeworks
―
Aptose Biosciences
―
Best Analysts Covering XFOR
1 Year
1 Year Success Rate
6/16 ratings generated profit
1 Year Average Return
-5.41%
reiterated a buy rating 6 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -5.41% per trade.
---